Sachin Kumar

Sachin Kumar

Auto-generated profile, based on publicly available information

Sachin Kumar


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 October 2023 in Cancers
Verified
Journal Article
Open access
PDF file
ARAhmad Raza
Ahmad Raza
MYMeng-Chi Yen
Meng-Chi Yen
Gangga AnuragaGangga Anuraga
Gangga Anuraga
ISIram Shahzadi
Iram Shahzadi
MMmuhammad waqar mazhar
muhammad waqar mazhar
Chih-Yang WangChih-Yang Wang
Chih-Yang Wang
Glioblastoma multiforme (GBM) is one of the most aggressive cancers with a low overall survival rate. The treatment of GBM is challenging due to the presence of the blood–brain barrier (BBB), which hinders drug delivery. Invasive procedures alone are not effective at completely removing such tumors. Hence, identifying the crucial pathways and biomarkers for the treatment of GBM is of prime importance. We conducted this study to identify the pathways associated with GBM. We used The Cancer Genome Atlas (TCGA) GBM genomic dataset to identify differentially expressed genes (DEGs). We investigated the prognostic values of the guanine nucleotide-binding protein G(i) alpha subunit (GNAI) family of genes in GBM using a Chinese Glioma Genome Atlas (CGGA) dataset. Within this dataset, we observed the association in the tumor microenvironment between the gene expression of GNAI subunit 3 (GNAI3) and a poor prognosis. MetaCore and gene ontology (GO) analyses were conducted to explore the role of GNAI3 in co-expressed genes and associated signaling pathways using a transcript analysis. Notable pathways included “Cytoskeleton remodeling regulation of actin cytoskeleton organization by the kinase effectors of Rho GTPases” and “Immune response B cell antigen receptor (BCR) pathway”. A single-cell analysis was used to assess GNAI3 expression in GBM. The results demonstrated that GNAI family genes, specifically GNAI3, were significantly associated with carcinogenesis and malignancy in GBM patients. Our findings suggest that the GNAI3 gene holds potential as a prognostic biomarker for GBM.

11 March 2026 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
SKSachin Kumar
Sachin Kumar
Chih-Yang WangChih-Yang Wang
Chih-Yang Wang
HLHelena Kishore Lalwani
Helena Kishore Lalwani
JNJuan Lorell Ngadio
Juan Lorell Ngadio
FWFitria Sari Wulandari
Fitria Sari Wulandari
HLHui-Pu Liu
Hui-Pu Liu
Background/Objectives: Glioblastoma (GBM) is the most aggressive primary brain tumor in adults and remains associated with poor prognosis despite multimodal therapy. Metabolic reprogramming, particularly increased dependence on glutamine, supports GBM bioenergetic, biosynthetic, and redox demands. This study aimed to systematically identify glutamine-associated metabolic regulators with prognostic relevance and biological plausibility in GBM. Methods: Transcriptomic data from TCGA and GTEx were analyzed using GEPIA2, with survival validation performed using the CGGA. Functional pathway enrichment, protein expression assessment, protein–protein interaction network analysis, tumor microenvironment evaluation, epigenetic profiling, and single-cell RNA sequencing validation were integrated to contextualize candidate genes. Pharmacogenomic correlation analysis and structure-based molecular docking were applied as supportive validation layers. Results: Ceruloplasmin (CP), Solute Carrier Family 25 Member 13 (SLC25A13), and Solute Carrier Family 38 Member 2 (SLC38A2) were selectively dysregulated and associated with poor clinical outcomes in GBM. CP was linked to redox regulation and stress-adaptive survival programs, SLC25A13 to mitochondrial metabolite exchange and glutamine-coupled nucleotide biosynthesis, and SLC38A2 to glutamine uptake, nutrient sensing, and mTORC1-MYC-associated growth signaling. Conclusions: CP, SLC25A13, and SLC38A2 emerge as clinically relevant glutamine-associated metabolic regulators in GBM, linking redox regulation, mitochondrial metabolite exchange, and glutamine-driven growth signaling. These findings highlight transport- and exchange-centered metabolic nodes as potential biomarkers and candidates for future metabolic targeting in GBM.

Verified
Journal Article
Open access
PDF file
SCShih-chieh Chen
Shih-chieh Chen
KCKai-Fu Chang
Kai-Fu Chang
CCChien-Cheng Chao
Chien-Cheng Chao
CLChung-Hsien Lin
Chung-Hsien Lin
CCChih-Hsuan Chang
Chih-Hsuan Chang
HLHui-Pu Liu
Hui-Pu Liu
Cytokines are central regulators of inflammation and immune responses within the tumor microenvironment and have been implicated in cancer progression and prognosis. However, the prognostic value of coordinated cytokine-related transcriptional programs across cancer types has not been systematically explored. Pan-cancer transcriptomic and clinical data were analyzed to construct a cytokine-related prognostic signature using least absolute shrinkage and selection operator (LASSO) Cox regression. Patients were stratified into high-risk and low-risk groups based on the derived risk score. Prognostic performance was evaluated in training and test cohorts, and biological relevance was assessed through survival analyses and pathway-level investigations. A 16-gene cytokine-related signature was established that consistently stratified patients into distinct prognostic groups across multiple cancer types. High cytokine-related risk scores were significantly associated with unfavorable survival outcomes and were linked to enhanced cell cycle activity, epithelial-mesenchymal transition, and extracellular matrix remodeling. Integration of the risk score with clinical variables improved individualized survival prediction. Immunohistochemical analyses further confirmed increased protein expression of representative risk-associated genes, including pannexin 1 (PANX1) and FERM domain containing 8 (FRMD8), in multiple tumor tissues compared with corresponding normal tissues. The cytokine-related prognostic signature captures key inflammatory and immune-related programs underlying tumor aggressiveness and provides a robust tool for pan-cancer risk stratification with potential clinical utility.

1 January 2026 in Oncology Research
Verified
Journal Article
Open access
WHWen-Hsin Hsu
Wen-Hsin Hsu
KCKai-Fu Chang
Kai-Fu Chang
CCChih-Hsuan Chang
Chih-Hsuan Chang
HLHui-Ru Lin
Hui-Ru Lin
CWChi-Jen Wu
Chi-Jen Wu
YLYungKuo Lee
YungKuo Lee
Background: Glycosylation and inflammation are pivotal in tumor progression, yet the specific glycosyltransferases bridging these processes remain poorly defined. This study investigated Exostosin-1 (EXT1), a key enzyme in heparan sulfate (HS) biosynthesis, as a mechanistic bridge connecting inflammation, stromal remodeling, and immune evasion-driven cancers. Methods: We used a multi-omics approach including Least Absolute Shrinkage and Selection Operator (LASSO) Cox regression on The Cancer Genome Atlas (TCGA) pan-cancer cohorts, transcriptomics, survival, single-cell RNA sequencing (scRNA-seq), DNA methylation profiling, pathway enrichment analysis (MetaCore), molecular docking, and immunohistochemistry (IHC) on pancreatic adenocarcinoma (PAAD) and lung adenocarcinoma (LUAD) tissue microarrays. Results: EXT1 was identified as one of only two genes overlapping inflammation- and glycosylation-related gene sets, strongly associated with poor overall survival (OS), disease-specific survival (DSS), and progression-free survival (PFS) across cancers, particularly in PAAD and LUAD. Pan-cancer profiling revealed broad EXT1 upregulation. ScRNA-seq localizedEXT1to stromal cells (pancreatic stellate cells, fibroblasts) and epithelial cells co-expressed with immune checkpoint markers. EXT1 promoter hypomethylation correlated with high expression and poor survival. Enrichment analysis of EXT1-correlated genes highlighted activation of critical pro-tumorigenic pathways, including transforming growth factor-β (TGF-β), lysophosphatidic acid (LPA), epidermal growth factor receptor-phosphoinositide 3-kinase-AKT–mitogen-activated protein kinase (EGFR-PI3K-AKT-MAPK), integrin-focal adhesion kinase-Rho GTPase (integrin–FAK–Rho), and epithelial–mesenchymal transition (EMT) pathways. IHC validated stage-dependent EXT1 overexpression in both PAAD and LUAD. Conclusion: This multi-omics study identifies EXT1 as a novel link between glycosylation and inflammation. It functions as a driver of stromal activation, immune checkpoint engagement, and tumor progression. EXT1 represents a clinically relevant biomarker and a promising therapeutic target in inflammation-driven cancers like PAAD and LUAD.

13 February 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
SCShih-chieh Chen
Shih-chieh Chen
KCKai-Fu Chang
Kai-Fu Chang
CCChien-Cheng Chao
Chien-Cheng Chao
CLChung-Hsien Lin
Chung-Hsien Lin
CCChih-Hsuan Chang
Chih-Hsuan Chang
HLHui-Pu Liu
Hui-Pu Liu
Background Cytokines are central regulators of inflammation and immune responses within the tumor microenvironment and have been implicated in cancer progression and prognosis. However, the prognostic value of coordinated cytokine-related transcriptional programs across cancer types has not been systematically explored. Methods Pan-cancer transcriptomic and clinical data were analyzed to construct a cytokine-related prognostic signature using LASSO Cox regression. Patients were stratified into high-risk and low-risk groups based on the derived risk score. Prognostic performance was evaluated in training and test cohorts, and biological relevance was assessed through survival analyses and pathway-level investigations. Results A 16-gene cytokine-related signature was established that consistently stratified patients into distinct prognostic groups across multiple cancer types. High cytokine-related risk scores were significantly associated with unfavorable survival outcomes and were linked to enhanced cell cycle activity, epithelial-mesenchymal transition, and extracellular matrix remodeling. Integration of the risk score with clinical variables improved individualized survival prediction. Immunohistochemical analyses further confirmed increased protein expression of representative risk-associated genes, including PANX1 and FRMD8, in multiple tumor tissues compared with corresponding normal tissues. Conclusions The cytokine-related prognostic signature captures key inflammatory and immune-related programs underlying tumor aggressiveness and provides a robust tool for pan-cancer risk stratification with potential clinical utility.